Abrilumab (INN;[1] development code AMG 181) is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.[2]

Abrilumab
Monoclonal antibody
Type?
SourceHuman
Targetintegrin alpha-4 beta-7
Clinical data
Other namesAMG 181
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6362H9806N1686O2014S52
Molar mass143803.34 g·mol−1

This drug was developed by MedImmune.

References

edit
  1. ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Abrilumab, American Medical Association.